ArticleNature communications2022
A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes.Frontiers in pharmacology · 2023Pooled it
- Multidimensional molecular mechanisms of drug resistance in breast cancer: Implications for clinical decision‑making and treatment strategies (Review).Oncology reports · 2026Review
- Research Progress on ROS Scavenging and Responsive Materials for Biomedical Applications.ACS omega · 2026Review
- Platinum nanozymes pursue cellular redox homeostasis: playing dual roles as pro-oxidants and antioxidants.Journal of nanobiotechnology · 2026Review
- Nanozyme for precision treatment of hepatocellular carcinoma.Materials today. Bio · 2026Review
- Transforming cisplatin into targeted photothermal chemotherapeutics through the platinum-phosphate coordination within a hyaluronan nanogel.Science advances · 2026Article
- DNA Nanotechnology-Enabled Precise Regulation of Nanozymes and Their Applications.Research (Washington, D.C.) · 2026Review
- Edge-rich Cu-NTheranostics · 2026Article
- Metal-Based Therapeutic Approaches for Overcoming Cancer Drug Resistance: Mechanisms, Drug Delivery Strategies, and Clinical Perspectives.Oncology research · 2026Review
- Emerging versatile nanozymes for the therapeutic and diagnostic applications of diseases.Journal of translational medicine · 2025Review
- Dual enzyme-driven redox homeostasis disruption with ultrasmall Pt-decorated MoSMaterials today. Bio · 2025Article
- Surface-Modified Nanozymes for Enhanced and Selective Catalysis.ACS applied materials & interfaces · 2025Review
- Biopolymer-based bone scaffold for controlled Pt (IV) prodrug release and synergistic photothermal-chemotherapy and immunotherapy in osteosarcoma.Journal of nanobiotechnology · 2025Article
- Corosolic acid increases the therapeutic effect of cisplatin on gastric cancer by regulating Gpx4-dependent ferroptosis.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Cartilage-targeting peptide-modified cerium oxide nanoparticles alleviate oxidative stress and cartilage damage in osteoarthritis.Journal of nanobiotechnology · 2024Article
- Metal-ligand cross-link strategy engineered iron-doped dopamine-based superstructure as peroxidase-like nanozymes for detection of glucose.Analytical and bioanalytical chemistry · 2024Article
- Atomic-scale strain engineering of atomically resolved Pt clusters transcending natural enzymes.Nature communications · 2024Article
- Catalytic Dual-Mode Immunotherapy: Anisotropic AuPt Heterostructure Decorated with Starry Pt Nanoclusters for Robust Cancer Photometalloimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Bio synthesis, comprehensive characterization, and multifaceted therapeutic applications of BSA-Resveratrol coated platinum nanoparticles.Scientific reports · 2024Article
- Metal nanoparticles for cancer therapy: Precision targeting of DNA damage.Acta pharmaceutica Sinica. B · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum (Pt) resistance in cancer almost inevitably occurs during clinical Pt-based chemotherapy. The spontaneous nucleotide-excision repair of cancer cells is a representative process that leads to Pt resistance, which involves the local DNA bending to facilitate the recruitment of nucleotide-excision repair proteins and subsequent elimination of Pt-DNA adducts. By exploiting the structural vulnerability of this process, we herein report a nuclease-mimetic Pt nanozyme that can target cancer cell nuclei and induce concurrent DNA platination and oxidative cleavage to overcome Pt drug resistance. We show that the Pt nanozyme, unlike cisplatin and conventional Pt nanoparticles, specifically induces the nanozyme-catalyzed cleavage of the formed Pt-DNA adducts by generating in situ reactive oxygen species, which impairs the damage recognition factors-induced DNA bending prerequisite for nucleotide-excision repair. The recruitment of downstream effectors of nucleotide-excision repair to DNA lesion sites, including xeroderma pigmentosum groups A and F, is disrupted by the Pt nanozyme in cisplatin-resistant cancer cells, allowing excessive accumulation of the Pt-DNA adducts for highly efficient cancer therapy. Our study highlights the potential benefits of applying enzymatic activities to the use of the Pt nanomedicines, providing a paradigm shift in DNA damaging chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.